• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Catalyst Pharmaceuticals Inc.

    11/10/25 8:17:56 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CATALYST PHARMACEUTICALS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    14888U101

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    14888U101


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,034,527.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,405,387.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,405,387.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CATALYST PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES, FLORIDA, 33134, UNITED STATES
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    14888U101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6405387.00
    (b)Percent of class:

    5.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    6,034,527

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    6,405,387

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:11/07/2025
    Get the next $CPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

    Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

    2/4/25 7:01:07 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Catalyst Pharma with a new price target

    Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

    11/18/24 8:40:25 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Catalyst Pharma with a new price target

    Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

    3/14/24 7:36:28 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today reported financial results for the third quarter of 2025 and provi

    11/5/25 4:06:45 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

    CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be named on the BioSpace 2026 Best Places to Work list for a second consecutive year, which is a testament to the exceptional team we've built at Catalyst," said Richard J. Daly, presid

    11/4/25 4:03:00 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

    CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025. Presentation Day: Monday, November 17, 2025Time: 2:00 pm (GMT)Webcast Link The webcast will be available under the Investors section on the Company's website, www.catalystpharma.c

    11/3/25 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Catalyst Pharmaceuticals Inc.

    SCHEDULE 13G - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    11/10/25 8:17:56 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

    8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    11/5/25 4:26:34 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Catalyst Pharmaceuticals Inc.

    10-Q - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

    11/5/25 4:02:31 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Compliance/Legal Officer Elsbernd Brian sold $609,000 worth of shares (30,000 units at $20.30) and exercised 112,475 shares at a strike of $2.24, increasing direct ownership by 44% to 271,039 units (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    9/10/25 5:00:26 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Compliance/Legal Officer Elsbernd Brian exercised 50,000 shares at a strike of $2.24 and sold $987,200 worth of shares (50,000 units at $19.74) (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    9/5/25 5:00:15 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tierney David S exercised 50,000 shares at a strike of $2.24 and sold $525,200 worth of shares (26,000 units at $20.20), increasing direct ownership by 7% to 379,620 units (SEC Form 4)

    4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

    8/28/25 5:00:43 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors

    CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da

    8/4/25 8:03:00 AM ET
    $CPRX
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

    CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b

    6/2/25 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

    CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

    10/8/24 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Financials

    Live finance-specific insights

    View All

    Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today reported financial results for the third quarter of 2025 and provi

    11/5/25 4:06:45 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

    CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market close on Wednesday, November 5, 2025. Catalyst's management team will host a conference call and webcast on Thursday, November 6, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast Details Date:November 6, 2025Time:8:30 AM ET

    10/22/25 8:03:00 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

    Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained Demand FIRDAPSE® Q2 2025 Net Product Revenue of $84.8 Million, Up 9.7% YoY; First Half 2025 Net Product Revenue of $168.6 Million, a 16.9% Increase Over Prior Year, Underscoring Sustained Momentum and Confidence in Long-Term Growth AGAMREE® Q2 2025 Net Product Revenue of $27.4 Million, Up 212.9% YoY; First Ha

    8/6/25 4:13:09 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    11/14/24 9:55:56 AM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    10/18/24 3:31:27 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

    SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

    10/17/24 12:14:52 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care